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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYData from the literature indicate that genomic imprintmarks are disturbed in human pluripotent stem cells (PSCs).GNAS is an imprinted
locus that produces one biallelic (Gsa) and four monoallelic (NESP55, GNAS-AS1, XLsa, and A/B) transcripts due to differential methyl-
ation of their promoters (DMR). To document imprinting at theGNAS locus in PSCs, we studiedGNAS locus DMRmethylation and tran-
script (NESP55, XLsa, and A/B) expression in human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs)
derived from two human fibroblasts and their progenies. Results showed that (1) methylation at the GNAS locus DMRs is DMR and cell
line specific, (2) changes in allelic transcript expression can be independent of a change in allele-specific DNAmethylation, and (3) inter-
estingly, methylation at A/B DMR is correlated with A/B transcript expression. These results indicate that these models are valuable to
study the mechanisms controlling GNASmethylation, factors involved in transcript expression, and possibly mechanisms involved in
the pathophysiology of pseudohypoparathyroidism type 1B.INTRODUCTION
Human pluripotent stem cells (PSCs) provide invaluable
models to studydevelopment, humandiseases, and regener-
ative therapies. They can be derived from blastocysts
(human embryonic stem cells [hESCs]) or directly reprog-
rammed from somatic cells (human induced pluripotent
stem cells [hiPSCs]) (MacDonald and Mann 2014; Sabour
and Scho¨ler 2012; Tobin and Kim 2012). They share the
unique property of self-renewal and are both expected to
express the paternal andmaternal imprints established dur-
ing gametogenesis and maintained following fertilization.
Imprinting maintenance and erasure are essential processes
required for the mammalian development (Girardot et al.,
2013; Laird 2013; Reik et al., 2001). However, hESCs are
derived from a period in mammalian development charac-
terized by global epigenetic remodeling, raising the possibil-
ity that the genomic imprint marks may be disturbed in
these cells, whereas it is argued that nuclear reprogramming
of hiPSCs could erase them (Li and Sasaki 2011; Takikawa
et al., 2013). Therefore, it is important to assess if methyl-
ation marks at imprinted loci are stable or subject to varia-
tion upon derivation technique and subsequent culture.
GNAS is an imprinted locus that produces several tran-
scripts comprising Gsa, the alpha-stimulatory subunit of432 Stem Cell Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Athe G protein; XLsa; A/B (also referred as 1A); NESP55;
and the antisense transcript GNAS-AS1. Due to differential
methylation of their promoters (DMR), XLsa, A/B,NESP55,
and GNAS-AS1 originate from one parental allele only.
XLsa, A/B, andGNAS-AS1 are transcribed from the paternal
allele; NESP55 is transcribed from the maternal allele
only. The promoter of Gsa is not differentially methylated,
and therefore, Gsa expression arises from both alleles in
most tissues (Figure 1). In a few specific tissues, however,
including the renal proximal tubule, the thyroid, the pitu-
itary, and the gonads, Gsa is expressed from the maternal
allele only (Bastepe and Ju¨ppner 2005; Hayward et al.,
1998a, b; Levine 2012; Linglart et al., 2013; Mantovani
et al., 2002; Plagge and Kelsey 2006; Weinstein et al.,
2001). Maternally and paternally inherited loss of function
of Gsa cause pseudohypoparathyroidism (PHP) type 1A
(OMIM 103580) and pseudoPHP, respectively (or progres-
sive osseous heteroplasia). Epigenetic changes at one or
several of the promoters of the GNAS locus cause PHP
type 1B (PHP1B) (OMIM 603233). All patients affected
with PHP1B share a loss of methylation (LOM) at the
maternal promoter of A/B, which results in suppressed
Gsa transcription in imprinted tissues. LOM can be
restricted to the A/B promoter of GNAS, as found in most
familial forms of PHP1B (autosomic dominant PHP1Buthors
Figure 1. Schematic Drawing of the GNAS
Locus
The GNAS locus is scaled, based on HG19. The
four differentially methylated regions stud-
ied in this report are represented below the
genomic line by black boxes (+ or methyl-
ated) or white boxes ( or unmethylated) on
the paternal (Pat) or maternal (Mat) allele.
Exons are indicated as black rectangles and
allelic origin of transcription as broken ar-
rows on the Pat or Mat allele. Positions and
number of analyzed cytosines regarding
methylation analysis are also indicated.
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GNAS Locus Imprinting in hESCs/hiPSCs[AD-PHP1B]). Alternatively, A/B DMR LOM can be associ-
ated with methylation changes at other DMRs of GNAS
on thematernal allele, as found in rare families carrying de-
letions removing an imprinting control element close to
the AS and NESP DMRs, or most frequently in patients
with sporadic PHP1B (80%–85% of PHP1B patients) (Bas-
tepe and Ju¨ppner 2005; Hayward et al., 1998a, b; Levine
2012; Linglart et al., 2013; Mantovani et al., 2002; Plagge
and Kelsey 2006; Weinstein et al., 2001).
The molecular mechanisms controlling the establish-
ment of imprinting at the GNAS cluster and leading to
the methylation defects in PHP1B are mostly unknown,
in part because of a paucity of suitable animal models
and lack of accessible Gsa-imprinted human tissues. Dur-
ing the murine embryonic development, the differential
methylation of exon 1A (A/B in humans) and Nespas/
Gnasxl (AS and XL in humans) DMRs is established during
the oogenesis (germline DMRs) whereas the differential
methylation of Nesp DMR occurs postfertilization (somatic
DMR), with a key role played byNesp transcription in estab-
lishing the specific-allele methylation at the Gnas locus
(Chotalia et al., 2009; Coombes et al., 2003; Liu et al.,
2000). A recent study analyzing a large number of human
fetal gonads from gestational weeks 6.5–22 suggested that
epigenetic reprogramming in human primordial germ cells
(hPGCs) probably involves, as observed in mice but with a
different timing, two distinct periods: an early wave of
genome-wide demethylation before 7 weeks of gestation
and a later wave of imprint erasure and changes in chro-
matin modifications after 9 weeks of gestation (Gkountela
et al., 2013; Laird 2013). Studies in hESCs and hPGCs indi-
cated that allelic silencing of A/B is established during the
gametogenesis (Frost et al., 2011) and that of XLsa already
established at 5 weeks postfertilization (supporting the
gametic specific-allele methylation of both A/B and XL
DMRs as observed in the mice) (Crane et al., 2009). The
complete allelic silencing of the NESP55 transcript occurs
during implantation 5–11 weeks after fertilization (Crane
et al., 2009; Rugg-Gunn et al., 2005a, b), in agreement
with a somatic DMR. Tissue-specific silencing of paternalStem CellGsa most likely takes place after 11 weeks postfertilization
and after tissue differentiation (Turan et al., 2014; Zheng
et al., 2001). A genome-wide DNA methylation revealed
the maintenance of GNASmethylation in hiPSCs with cul-
ture, although hypermethylation and hypomethylation
were also observed (Nazor et al., 2012).
In an effort to document imprinting at the GNAS locus
and contribute to the development of models allowing its
dynamic study and tissue-specific silencing of paternal
Gsa in (patho)physiological conditions in humans, we
studied methylation at the four GNAS DMRs in hESCs
and hiPSCs and their progenies. We also examined the
expression of four GNAS transcripts (Gsa, A/B, XLsa, and
NESP55) in hiPSCs and derivatives.RESULTS
Characterization of Cell Lines
Somatic, pluripotent stem, and differentiated cells studied
are presented in Table 1. Characterization of all hiPSC
and ESC lines revealed a normal karyotype (including the
VUBO1P91 cell line, studied at a high passage), expression
of pluripotency markers, and expression of markers of
the three germ layers upon in vitro embryoid bodies dif-
ferentiation as illustrated in Figure 2 for hiPSC i90c17
line. In addition, all neural stem cells (NSCs) and mesen-
chymal stem cells (MSCs) expressed, respectively, the neu-
ral markers Nestin and Sox2 and themesenchymalmarkers
CD29, CD44, CD73, and CD166, as illustrated in Figure 2
for NSCs and MSCs derived from hiPSC i90c17 line.
Comparison of overall transcript levels between the
various cell types by quantitative real-time PCR (qRT-
PCR) indicated similar patterns of expression. When com-
paring fibroblasts and derived hiPSCs, an increase in all
transcripts expression was observed. When comparing
PSCs (hESCs and hiPSCs) in both NSC and MSC progenies,
a decrease in NESP55, XLsa, and A/B transcripts expression
was present, whereas Gsa transcript expression increased
upon differentiation (Figure S1 available online).Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Authors 433
Table 1. Somatic, Pluripotent Stem, and Differentiated Cells Studied
Somatic Cells PSCs Differentiated Cells (Progenies) Allelic Expression Overall Transcript Levels
h fibroblasts IMR90 (XX) hiPSC i90c01 (retrovirus) MSC/NSC Fb/hiPSC/MSC Fb/hiPSC/MSC/NCS
hiPSC i90c17 (episome) MSC/NSC Fb/hiPSC/MSC/NSC Fb/hiPSC/MSC/NSC
h fibroblasts GM04603 (XY) hiPSC 4603c27 (retrovirus) MSC/NSC Fb/hiPSC/MSC/NSC Fb/hiPSC/MSC/NSC
hiPSC 4603 polyF (retrovirus) Fb/hiPSC Fb/hiPSC
hESC VUB01 (XY) NSC 0 Fb/hESC/NSC
hESC W09 (XX) MSC 0 Fb/hESC/MSC
hESC RC9 (XY) 0
hESC SA01 (XY) NSC 0 Fb/hESC/NSC
For each cell line, whether overall (shown in Figure S1) and allelic (shown in Figure 5) transcript expressions were analyzed is indicated. Methylation at
the GNAS DMRs was studied for all cells except hiPSC i90_c01 NSC. Fb, fibroblast; h, human; hESC, human embryonic stem cells; hiPSC, human induced
pluripotent stem cells; MSC, mesenchymal stem cells; NSC, neuronal stem cells. ‘‘0’’ indicates homozygosity at the DNA level (all hESC). Only heterozygous
cells at the DNA level were analyzed for transcript expression. Overall and allelic expressions were analyzed as described in the Experimental Procedures
section.
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In order to study the maintenance of imprinting at the
GNAS locus, we quantified and compared methylation at
the GNAS locus DMRs in eight PSCs (four hESCs and four
hiPSCs), their progenies (four MSCs and four NSCs), and
the two parental fibroblast cell lines and controls.
hESCs/hiPSCs
We first compared methylation indices at the GNAS DMRs
measured in the four hESCs and four hiPSCs (Figures 3 and
S2). Results showed that percent of methylation at each
DMRwas not significantly differentwhen comparinghESCs
and hiPSCs (NESP: hESCs: 43.7% ± 2.76%, hiPSC: 46.8% ±
3.07%; AS: hESC: 36.9% ± 16.42%, hiPSC: 34.3% ±
17.33%; XL: hESC: 49.0% ± 7.27%, hiPSC: 48.5% ± 4.6%;
A/B: hESC: 38.6% ± 12.57%, hiPSC: 35.7% ± 13.73%; p >
0.05 for each DMR; mean ± SD; n = 4 for all groups).
PSCs/Controls
Because methylation at the GNAS DMRs was not signifi-
cantly different in hESCs and hiPSCs, we then compared
methylation at each GNAS DMRs comparing all PSCs
(hESCs + hiPSCs) to that measured in blood DNA from
20 controls (Figure 3). Results indicated that percent of
methylation at the NESP and XL DMRs was not signifi-
cantly different when comparing PSCs and controls
(PSCs, NESP: 45.2% ± 3.15%, XL: 48.8% ± 5.63%; con-
trols, NESP: 49.3% ± 2.34%, XL: 47.28% ± 3.44%; p >
0.05; Figure 3). In contrast, percent of methylation at
the AS and A/B DMRs was significantly lower when
comparing PSCs and controls (PSCs, AS: 35.6% ±
15.69%, A/B: 37.2% ± 12.29%; controls, AS: 49.5% ±
1.39%, A/B: 51.9% ± 2.07%; p < 0.01 and 0.001, respec-
tively, for AS and A/B; mean ± SD; n = 8 for PSCs and
20 for controls).434 Stem Cell Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The APercent of methylation for each DMR in the two parental
fibroblast cell lines was within the range of values obtained
in genomic DNA from controls (Figure 3).
We also compared the dispersion of GNAS DMR methyl-
ation between groups. The methylation scatter at the AS
and A/B DMRs, but not at the NESP and XL DMRs, was
significantly higher at the AS and A/B DMRs in PSCs
compared to that in controls (PSCs, AS: 12.5% ± 8.66%,
A/B: 8.5% ± 8.80%; controls, AS: 1.2% ± 0.69%, A/B:
1.6% ± 1.28%; p < 0.001 and p < 0.01, respectively, for AS
and A/B; mean ± SD; data not shown). These results further
support that the methylation at the AS and A/B DMRs is
less stringent than that at the NESP and XL DMRs in
PSCs and compared to controls.
PSCs/Progenies
PSCs were differentiated in four MSCs (three from hiPSCs
and one from hESCs) and four NSCs (two from hiPSCs and
twofromhESCs).WhencomparingNSCprogenies toappro-
priate PSCs, an increase in percent of methylation was
observed in 2/4, 4/4, and 2/4, respectively, at the NESP, AS,
and A/B DMRs and a decrease in 1/4 and 2/4, respectively,
at the XL and A/B DMRs (Figures 4 and S3). Changes in
percent of methylation were observed for NSC obtained
from both hESCs and hiPSCs (Figures 4 and S3). When
comparing MSC progenies to appropriate PSCs, methyl-
ation at NESP, XL, and A/B DMRs were similar. As in NSC,
an increase in percent of methylation at AS DMR was also
observed in MSC compared to appropriate PSCs. Thus, at
the AS DMR, percent of methylation was significantly
higher in MSC and NSC progenies compared to PSCs (Fig-
ure 4) (progenies: 66.1% ± 20.63%; controls: 39.0% ±
13.42%;p<0.001;mean± SD; n =6 forprogenies andPSCs).uthors
Figure 2. Characterization of i90c17
Human Induced Pluripotent Stem Cells
and Neural Stem Cells and Mesenchymal
Stem Cells Derived from i90c17 hiPSC Line
(A) Phase-contrast image of an i90c17
hiPSCs colony on feeder cell.
(B) Immunostaining showing the expression
of the pluripotency markers TRA1-60,
NANOG, SSEA4, and OCT4 in i90c17 hiPSC
line.
(C) G-banding chromosome analysis of
i90c17 hiPSCs showing a normal karyotype
(46, XX).
(D) In vitro embryoid body formation from
i90c17 hiPSCs showed three germ layer dif-
ferentiation as illustrated by the presence of
endodermal AFP+ cells, neuroectodermal
PAX6+ cells, and mesodermal SMA+ cells.
(E) Phase-contrast image of hiPSCs i90c17-
derived NSCs.
(F) Immunostaining showing the expression
of the neural (Nestin and Sox2) and prolif-
erating (Ki67) markers in hiPSCs i90c17-
derived NSCs.
(G) Phase-contrast image of i90c17 hiPSCs-
derived MSCs.
(H) Flow cytometry analysis of CD29, CD44,
CD73, CD106, and CD166 expression in
i90c17 hiPSCs-derived MSCs.
hiPSC, human pluripotent stem cell; MSC,
mesenchymal stem cell; NSC, neural stem
cell. The scale bars represent 200 mm. See
also Figure S1.
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and Progenies
We determined that the two parental fibroblasts were het-
erozygous for the polymorphism rs7121 T/C in exon 5
(GNAS T393C) at the genomic DNA level (%T: 49.7% and
48.2% in IMR90 and GM04603, respectively) and that
their derivative cells maintained heterozygosis (data not
shown), thereby allowing analysis of GNAS transcript
allelic expression as a function of reprogramming and dif-
ferentiation. All hESCs were homozygous for rs7121 (data
not shown).
NESP55 transcripts were detected only in 3/4 hiPSCs
and showed monoallelic expression (%T expression:
100% and 98% in hiPSCs 4603_c27 and polyF, respec-Stem Celltively; %C: 94% in hiPSC i90_c01) (Figures 5, S4, and
S5); they were not detected in fibroblasts or in progenies.
As indicated in the Experimental Procedures section, given
that NESP55 is essentially maternally expressed, transcript
expression is thus expressed as ‘‘percent maternal allele
ratio.’’
As expected, expression ofGsa transcripts was biallelic in
the two parental fibroblasts (58.40% and 56.60% maternal
allele ratio in fibroblasts i90 and i4603, respectively) (Fig-
ures 5 and S3). Gsa remained biallelic after reprogramming
in hiPSCs and differentiation in progenies (maternal allele
ratio: 47.4% ± 5.8% and 54.8% ± 2.71%, respectively, in
hiPSCs and hiPSC progenies; mean ± SD; n = 6) (Figures 5
and S5).Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Authors 435
Figure 3. Methylation Quantification at the DMRs of GNAS in
PSCs Compared to Parental Fibroblasts
Methylation at each of the four DMRs was similar comparing hESCs
(B) and hiPSCs (C) and for NESP and XL DMRs, similar to 20 control
subjects (-) and parental fibroblasts (,). Methylation at the AS
and A/B DMRs was significantly lower when comparing PSCs and
controls (**p < 0.01; ***p < 0.001). Cell cultures, quantification of
methylation, and statistical analysis were performed as described in
the Experimental Procedures section. See also Figure S2.
Figure 4. Methylation Quantification at the Four DMRs of GNAS
in PSCs Compared to Progenies
Methylation at the GNAS locus is affected both as a function of cell
type (NSC - versus MSC ,) and DMRs: changes in percent of
methylation were observed at the NESP, XL, and A/B DMRs when
comparing NSC, but not MSC, to appropriate PSCs (hiPSCs: C;
hESCs:B); methylation at the AS DMR increases in both MSC and
NSC and was significantly higher than that in PSCs (***p < 0.001).
Cell cultures, quantification of methylation, and statistical analysis
were performed as described in the Experimental Procedures sec-
tion. See also Figure S3.
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GNAS Locus Imprinting in hESCs/hiPSCsExpression of XLsa transcripts was monoallelic in the
two parental fibroblasts and showed, as expected, paternal
expression (3.8% and 3.6%maternal expression in i90 and
in 4603, respectively) (Figures 5 and S5). Surprisingly, after
reprogramming in hiPSCs, XLsa was biallelic (maternal
allele ratio 43.1% ± 3.86%; mean ± SD; n = 4) in all cells.
In MSC- and NSC-differentiated cells, XLsa expression
was again monoallelic (maternal allele ratio 3.9% ±
4.61%;mean ± SD; n = 5), except in one NCS line, in which
it stayed biallelic.
As observed for XLsa transcripts, expression of A/B tran-
scripts was also monoallelic in the two parental fibroblasts
with paternal expression (5.2% and 0% maternal expres-
sion in i90 and in 4603, respectively). Monoallelic expres-
sion of A/B transcript was conserved in the two hiPSC i90
clones (maternal allele ratio 0% and 0.8%), but not in the
hiPSC 4603 clones, in which expression of A/B transcripts
increased and presented partial allelic and biallelic
(maternal allele ratio 21.3% and 41.2%) (Figures 5 and
S3). In MSC- and NSC-differentiated cells, A/B expression
was monoallelic and paternally expressed (maternal allele
ratio 4.26% ± 3.89%; mean ± SD; n = 5), except in one
NCS line, in which it increased and became biallelic
(maternal allele ratio 59.1%). The rs7121 polymorphism
is not present in GNAS-AS1 cDNA, therefore precluding
GNAS-AS1 allelic expression.436 Stem Cell Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The ACorrelation between DMR Methylation and
Allelic Expression
In ‘‘normal’’ conditions, XL and A/B promoters are differ-
entially methylated (i.e., methylated on the maternal
allele) and XLsa and A/B transcript expression is described
as monoallelic (expression of 90%–100% of a major
paternal allele). Changes of methylation are usually associ-
ated with changes in parental transcript expression. In or-
der to determine if XLsa and A/B transcript expression
was correlated to GNAS DMR methylation, we correlated
allelic expression to methylation at the XL and A/B GNAS
DMRs in fibroblasts and derivatives. We found that the
allelic expression of A/B transcripts, but not that of XLsa
with XL DMR, was correlated with A/B DMR methylation
(Figures 6A and 6B): the ratio of A/Bmaternal allele expres-
sion decreased when methylation at A/B DMR increased
(Pearson r: 0.8974, p = 0.001 and Pearson r: 0.4425, p =
ns for A/B and XL, respectively). Gsa allelic expression
was not correlated with percent methylation of A/B DMR
or with A/B transcript expression (data not shown). Allelicuthors
Figure 5. Allelic Transcript Expression in Parental Fibroblasts,
hiPSCs, and Progenies
NESP55 transcript, detected in three hiPSC clones, was monoallelic.
XLsa expression was monoallelic in the two parental fibroblast (Fb)
lines, biallelic in the four hiPSC clones, and returned to monoallelic
expression in progenies except one (NSC,-). A/B expression was
monoallelic in the two parental fibroblast lines, in 2/4 hiPSC
clones, and in progenies (Freson et al., 2008) except one (NSC,-).
Gsa was biallelic in the two parental fibroblast lines, the four hiPSC
clones, and progenies. Cell cultures and allelic transcript expression
were performed as described in the Experimental Procedures sec-
tion. Expression for GNAS transcripts are expressed as percent
maternal allele ratio, based on the allele expression of the mater-
nally expressed NESP55 transcript (see Experimental Procedures for
details). Biallelic expression was defined for maternal allele ratio
comprised between 40% and 60% and monoallelic expression for
maternal allele ratio comprised between 90% and 100% and 0% and
10%. See also Figures S4 and S5.
Figure 6. Correlation between Methylation and Allelic Expres-
sion for A/B and XLsa
The allelic expression of A/B transcript (A), but not that of XLsa
(B), correlates with the methylation at their DMRs (Pearson r: A/B:
0.8974, p = 0.001; XL: 0.4425, p = not significant). Cell cultures,
quantification of DMR methylation, and analysis of allelic transcript
expression were performed as described in the Experimental Pro-
cedures section. GNAS transcripts are expressed as percent maternal
allele ratio, based on the allele of the maternally expressed NESP55
transcript (see Experimental Procedures for details).
Stem Cell Reports
GNAS Locus Imprinting in hESCs/hiPSCstranscript expression analysis was not available for GNAS-
AS1 and was available in only three samples for NESP55,
precluding any correlation (data not shown).DISCUSSION
To assess if methylation marks at the GNAS locus were
maintained in hESCs and hiPSCs or subjected to variation
upon derivation technique and subsequent culture, we
quantified and compared methylation at the GNAS locus
in hESCs and hiPSCs (four cell lines each). Our results
showed that methylation at the four DMRs was similar in
hESCs and hiPSCs. These results are consistent with a
whole-genome single-base resolution DNA methylome
study by Lister et al. (2011) reporting globally similar
methylation comparing hESC and hiPSC methylomes. In
addition, we found that methylation at the paternally im-
printed NESP (maternal expression of the transcript) and
maternally imprinted XL (paternal expression of the tran-Stem Cellscript) DMRs was maintained in all PSCs (hESCs and
hiPSCs) and similar to that in controls and parental fibro-
blasts, in contrast to the two maternally imprinted AS
and A/B DMRs.
Twomain conclusions can be drawn from these observa-
tions. First, previous studies have indicated that epigenetic
instability is a rare occurrence in hESCs but, in contrast,
that the differential methylation that marks imprinted
loci could be erased during nuclear reprogramming of so-
matic cells (Frost et al., 2011). Analysis of germline methyl-
ation imprints in human PSCs has revealed some insta-
bility and this independently of the parental origin of the
imprint (Lund et al., 2012; Nazor et al., 2012; Rugg-Gunn
et al., 2007; Takikawa et al., 2013; Tobin and Kim 2012).
In this regard, aberrant DNAmethylation at thematernally
imprinted H19 and paternally imprinted KCNQOT1 genes
in iPSCs has been reported (Lister et al., 2011). Our results
indicate that the control of GNAS genomic methylation
imprinting stability does not vary specifically as function
of the PSC type (hESCs versus hiPSCs) and is independent
of the reprogramming procedure. This is further supported
by the similar methylation pattern observed for two clones
obtained from the same parental fibroblast either by
retroviral or episomal reprogramming methods. Second,
our results indicate that the control of methylation at the
NESP and XL DMRs (paternally and maternally imprinted,
respectively) is more stringent than that at AS and A/B
DMR (both maternally imprinted). NESP DMR methyl-
ation analyzed in two studies was reported differentially
methylated in the majority of hESC lines with exceptional
loss or gain of methylation (Frost et al., 2011; HuntrissReports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Authors 437
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GNAS Locus Imprinting in hESCs/hiPSCset al., 2011). Methylation of XL DMR reported in only two
human in vitro fertilization blastocysts was variable (4.8%
and 77.1%) (Huntriss et al., 2011). Our results further docu-
ment and enrich these observations. In all cases of DMR
methylation instability, we observed demethylation and
not hypermethylation, indicating that whatever the un-
derlying mechanism, AS and A/B are prone to demethyla-
tion during PSC derivation or maintenance. Why the
control of methylation at the AS and A/B DMRs is less
stringent than that at the NESP and XL DMRs in PSCs is
not explained. Methylation at the A/B DMR was low in
the polyclonal iPSC04603_polyF cell line and normal
in the monoclonal iPSC04603_c27 line, both derived
from the same parental fibroblasts, raising the possibility
that clonality may affect methylation results.
An important aspect of PSC research is their theoretical
ability to be differentiated into any cell type, including cells
expressing tissue-specific silencing of paternal Gsa, as
described for Gsa. However, for such studies, it is critical
to fully control the differentiation of these PSCs into spe-
cific cellular types of interest. Thus, our next step was to
study methylation marks upon differentiation of PSCs.
Our results indicate that methylation at the GNAS locus is
affected both as a function of cell type (NSC versus MSC)
and DMRs. Indeed, methylation changes at the NESP and
A/B DMRs were observed only upon differentiation into
NSC, not MSC. In addition, we observed an increase in
AS methylation in all progenies (NSC and MSC), reaching
hypermethylation levels in 4/8. Few reports, and none for
the GNAS locus to our knowledge, have addressed the issue
of DMRmethylation upon ‘‘re’’differentiation of PSCs into
progenies in human cells. The pattern associating gain of
methylation at NESP and loss of methylation at A/B and/
or XL DMRs of GNAS is reminiscent to that of patients
affected with sporadic PHP1B. Whereas it is tempting to
speculate that changes upon reprogramming and epige-
netic changes causing PHP1B are connected, the molecular
mechanisms causing these changes are not identified. In
contrast to our results in PSCs, loss of methylation at the
AS DMR of GNAS is common in sporadic PHP1B (Maupe-
tit-Me´houas et al., 2011) as observed for the A/B and XL
DMRs, also methylated on the maternal allele). The mech-
anisms causing the epigenetic changes in PHP1B are under
investigation and multiple. Some common mechanism
might exist during reprogramming and PHP1B. Further
studies analyzing the specific increase in AS methylation
as well as the changes in other DMRsmethylation observed
in progenies from hESCs and hiPSCs may help understand
the mechanisms whereby methylation at each DMR is
controlled in physiology and the mechanisms leading to
methylation defect in PHP1B.
The notion that loss of methylation at the GNAS DMRs
controls transcript expression ismostly intuitive, with little438 Stem Cell Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Aavailable direct evidence. Freson et al. (2008) showed
decreased methylation at XL DMR and increased expres-
sion of the XL protein in platelets. Loss of methylation at
exon A/B is associated with an increase in the levels of
the noncoding exon A/B RNA and a loss of Gsa expression
(Bastepe and Ju¨ppner 2005; Fro¨hlich et al., 2010). Studies
in mice have shown that paternal deletion of the exon
1A region results in reversal of Gsa allelic silencing with
biallelic expression of Gsa (Liu et al., 2000; Williamson
et al., 2004). Monoallelic expression of Gsa has been re-
ported in a few studies and mainly mouse studies (for re-
views, see Bastepe and Ju¨ppner, 2005; Hayward et al.,
2001; Levine, 2012; Linglart et al., 2013; Mantovani
et al., 2012; Plagge and Kelsey, 2006; Weinstein et al.,
2007). Human tissues expressing paternal Gsa allelic
silencing are not easily accessible, and the correlation be-
tween transcript expression andDMRmethylation is rarely
reported. Predominant maternal origin of transcription of
Gsa in human thyroid gland and gonads has been reported
(Mantovani et al., 2002).
Using the distinguishing parental single-nucleotide
polymorphism rs7121, we correlated allelic expression
and DMR methylation in hiPSCs and after differentiation
for the three imprinted transcripts (A/B, XLsa, and
NESP55) and also defined their parental expression as
well as that of Gsa. Allelic expression of the maternally
imprinted A/B transcripts varied as a function of the cell
line. As indicated above, A/B DMR has a maternal-specific
germline methylation. It is therefore expected that, in
hiPSCs and progenies, the expression of the A/B transcripts
originates predominantly from the paternal allele. This was
observed in hiPSC clones and progenies derived from one
fibroblast line, but not from the other. Importantly, how-
ever, we found that A/B transcript expression was corre-
lated with the degree of methylation at the A/B DMR,
indicating that allelic-silencing mechanism of A/B expres-
sion is methylation dependent.
Evidence from AD-PHP1B patients as well as mouse
models indicates that the expression levels of the two tran-
scripts, exon A/B and Gsa, are oppositely regulated in cis in
imprinted tissues (Plagge and Kelsey 2006; Williamson
et al., 2004). Absence of paternal Gsa transcript expression
is attributed at least in part to the prevention ofGsa expres-
sion by the expressed A/B transcript. As expected, we
detected biallelic expression of Gsa in all hiPSCs and fibro-
blasts, independently of A/B DMR methylation and tran-
scription. Regarding the results in progenies, tissue-specific
silencing of paternal Gsa has been described in brown fat
cells (Williamson et al., 2004) of mesenchymal origin)
and specific neurons (Chen et al., 2009); however, we do
not observe Gsa allelic silencing in the MSC and NSC stud-
ied. The MSC and NSC analyzed here have not reached
the differentiation status of brown fat cells and imprinteduthors
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requirement of ‘‘terminal’’ cell differentiation for Gsa
allelic silencing to occur, as previously shown in the kidney
(Turan et al., 2014; Zheng et al., 2001).
Inmost tissues, XLDMRhas amaternal-specific germline
methylation; thus, XL DMR methylation, absence of
maternal XLsa transcription, and monoallelic paternal
expression are expected in hiPSCs and progenies. Surpris-
ingly, the paternally expressed imprinted XLsa transcript
showed biallelic expression in all hiPSC clones from the
two parental fibroblast lines but, as expected, monoallelic
expression in all progenies (except one, also unstable for
A/B). Intriguingly, this biallelic expression of XLsa in all
hiPSC clones was observed in spite of a maintained XL
DMR methylation and thus was independent of a change
in allele-specific DNA methylation. This indicates that
imprinting mechanism of XLsa transcript expression is
not methylation dependent (at least mostly).
Correlation between allelic expression of imprinted
genes including NESP55 and methylation of identified
DMR has been previously reported in hESCs (Adewumi
et al., 2007; Kim et al., 2007; Rugg-Gunn et al., 2007). An
association between the variability observed in inter-cell
line allelic expression status and the DMR DNA methyl-
ation was present in one study (Kim et al., 2007), but not
others in which monoallelic NESP55 expression associated
with maintenance in NESP DMR methylation in hESCs
(Adewumi et al., 2007; Rugg-Gunn et al., 2007). We de-
tected the maternally expressed imprinted transcript
NESP55 in three hiPSC samples. In contrast to A/B and
XLsa transcripts, expression was monoallelic in these
hiPSCs. This stability in the monoallelic expression of
NESP55 in hiPSCs raises the possibility that the process
that maintains methylation at NESP DMR (or protect the
unmethylated allele against aberrant methylation) might
differ for NESP whose imprint is acquired postfertilization.
In summary, our studies indicate that (1) methylation at
the GNAS locus DMRs is DMR and cell line specific, (2)
methylation at the A/B DMR is correlated with A/B tran-
script expression, and (3) changes in allelic transcript
expression can be independent of a change in allele-spe-
cific DNA methylation. The study of parental, reprog-
rammed, and differentiated cells should provide a model
for studying the mechanisms controlling GNAS methyl-
ation, such as hydroxymethylation (Smallwood and Kelsey
2012); factors involved in transcript expression; and
possibly mechanisms involved in the pathophysiology of
PHP1B. This model will benefit from the possibility of
differentiating PSCs in cell types in whichGsa is paternally
silenced, such as BAT (Elabd et al., 2009) or proximal tubule
(Montserrat et al., 2012) as shown for Angelman and
Prader-Willi syndromes, two neurodevelopmental disor-
ders of genomic imprinting (Chamberlain et al., 2010).Stem CellEXPERIMENTAL PROCEDURES
Cell Lines
Human Embryonic Stem Cells
Four hESC lines were studied (Table 1). The hESC line VUB01 (XY;
passages 80–100) was derived at the Vrije Universiteit Brussels, H9
(XX; passages 50–60; WA09) by theWiCell Institute, and RC9 (XY;
passages 20–40) by Roslin Cells. The hESC line SA01 (XY; passages
30–50) is distributed by Cellartis.
Induced Pluripotent Stem Cells
hiPSC lines were obtained by reprogramming of two fibroblast
lines (IMR90 and GM04603) obtained from the Coriell Institute
either by retroviral or episomal methods as previously reported
(Mangeot et al., 2011; Yu et al., 2009). For IMR90 (XX), two clones
were studied: one obtained by retroviral methods (i90_c01) and
one by episomal methods (i90_c17). For GM04603 (XY), a poly-
clonal (iPSC04603_polyF) and a clonal (iPSC04603_c27) line
were studied (Table 1).
Pluripotent Stem Cell Culture
All PSC lines except RC9 were maintained on a feeder layer of
mitomycin-C-inactivated murine embryonic fibroblast cells in a
humidified 5% CO2 incubator at 37C, in KnockOut (KO)-Dulbec-
co’s modified Eagle’s medium supplemented with 20% KO serum
replacement, 1 mM L-glutamine, 1% nonessential amino acids,
0.1 mM b-mercaptoethanol, and 10 ng/ml basic (b)fibroblast
growth factor (FGF) (all from Invitrogen). RC9 was maintained
on a feeder-free system composed of CellStart matrix and StemPro
medium supplemented with 10 ng/ml basic (b)FGF (Invitrogen).
Cultures were fed daily and manually passaged every 5–7 days.
Quality control of the PSCs was performed as suggested by the In-
ternational Stem Cell Banking Initiative (2009) and showed
normal karyotypes and expression of stemness markers.
Differentiation
Differentiation of PSCs into mesenchymal (MSC) (hESC lines:
W09; hiPSC: i90_c01, i90_c17, and 4603_c27) and neural (NSC)
(hESC lines: SA01 andVUB01; hiPSC: i90_c17 and 4603_c27) prog-
enies was performed as previously reported (Benchoua and
Peschanski 2013; Chambers et al., 2009; Giraud-Triboult et al.,
2011; Guenou et al., 2009) (Table 1).
DNA Extraction
Genomic DNAwas extracted from parental fibroblasts, undifferen-
tiated and differentiated PSC lines (except one, NSC i90c01; Table
1), and from peripheral blood mononuclear cells from 20 control
subjects using Gentra Kit extraction (QIAGEN) according to the
manufacturer’s protocol. Informed written consent was obtained
from the controls for genomic DNA (gDNA) analysis.
Quantification of DNA Methylation
Quantification of GNAS DMRs DNA methylation was performed
by pyrosequencing as described in Supplemental Information
and Maupetit-Me´houas et al. (2013). Six hundred nanograms
of DNA were bisulfite converted (EZ DNA Methylation-GoldReports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The Authors 439
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microliter of bisulfite-converted DNAwas then amplified with spe-
cific primers for each DMR (A/B, XL, AS, and NESP). Pyrosequenc-
ing reactions were carried out on a PyroMark Q96 ID (QIAGEN)
using either one sequencing primer for two distinct bisulfited
PCR products (NESP, AS, and XL DMRs) or two different
sequencing primers of one bisulfited PCR product (A/B DMR).
Primer sequences and PCR conditions are presented in Table S1.
The peak heights were determined using the provided software
(PyroMark Q24 v2.0.6.20). Results are the mean ± SD of methyl-
ation measured at each cytosine for each DMR (NESP and XL 5
cytosines; AS: seven cytosines; A/B: eight cytosines). Replicate dif-
ferences between <10% and 10% were considered inherent to the
technique. In the rare cases of differences >10%, additional anal-
ysis pyrosequencing was performed. Five specific DNAs were
included in each run and served as internal standards to ensure
repeatability: unmethylated DNA (whole-genome amplified con-
trol DNA generated using the REPLI-g Mini Kit [QIAGEN]), fully
methylated DNA (unmethylated DNA treated with SSI DNAmeth-
yltransferase [New England Biolabs]), oneDNAprepared froma pa-
tient carrying an 1.7 Mb 20q paternal deletion comprising the
GNAS locus (I. Garin, F.M. Elli, A.L., C.S., L. de Sanctis, P. Bordogna,
A. Pereda, J.T.R. Clarke, C. Kannengiesser, R. Coutant, Y. Tene-
baum-Rakover, International Clinical Group for PHP, EuroPHP
Consortium, G.P. de Nanclares, and G. Mantovani, unpublished
data), one DNA obtained from a patient with paternalGNAS dupli-
cation (Maupetit-Me´houas et al., 2013), and one control DNA.
Complementary DNA
Total RNA were extracted from 1 3 106 frozen cells pellet using
Trizol reagent (Invitrogen) followed by a treatment in the RNeasy
MinElute cleanup Kit (QIAGEN) according to the manufacturer’s
protocol. Integrity of RNAwas verified on 1.5% agarose gel electro-
phoresis. One microgram total RNA digested by DNaseI (Fermen-
tas) was reverse transcribed using either hexamer random primers
(for the transcript allelic expression analysis, see below) or oligo
(dT) primers (for the quantitative real-time PCR, see below; Rever-
tedAid H Minus First Strand cDNA synthesis Kit; Fermentas) ac-
cording to the manufacturer’s protocol.
GNAS rs7121 Polymorphism Analysis in Genomic
and cDNA
For gDNA, 200 ng samples were PCR amplified with forward and
reverse primers localized in introns 3 and 5, respectively, covering
exons 4 and 6 of GNAS (exons common to Gsa, XLsa, A/B, and
NESP55) (Table S2). In order to allow analysis of C and Tallele ratio
by bidirectional pyrosequencing (see below), two PCRs were per-
formed for each product, with either the forward or reverse primer
being biotinylated. DNA PCR products were checked by migration
on 1.5% agarose gel electrophoresis.
For cDNA, 1 ml of cDNA was amplified with a forward-specific
primer forGsa,XLsa, A/B, andNESP55 transcripts, localized in their
respective exon 1, and a reverse primer common of all transcripts
except GNAS-AS1 localized in exons 9 and 10 (Table S2). As for
gDNA, two PCRs were performed for each product, with either the
forward or reverse primer being biotinylated. cDNA PCR products
were checked by migration on 1.5% agarose gel electrophoresis.440 Stem Cell Reports j Vol. 3 j 432–443 j September 9, 2014 j ª2014 The AHeterozygosity at theGNASPolymorphism rs7121 and
Transcript Allelic Expression Analysis
C and T allele ratio was analyzed by bidirectional pyrosequencing
using forward- and reverse-sequencing primers localized in exon 5
(Table S2) on PCR products obtained from gDNA and cDNA
(described above). Ratios were calculated using the Pyrosequenc-
ing software. A similar approach has been reported (Klenke et al.,
2011). DNA heterozygosity was defined for C (or T) allele ratio
comprised between 40% and 60%.
Comparison of C or Tallele ratio of cDNA samples were analyzed
only from heterozygous gDNA samples for rs7121 (T393C). When
detected, NESP55 transcript expression was monoallelic (>94% C
in clone hiPSC90_c01 and >94% T in clone hiPSC 4603_c27 and
polyF) (Figure S3; Results). Given that in ‘‘physiological’’ condi-
tions, NESP55 is essentially maternally expressed, expression for
GNAS transcripts is thus expressed as percent maternal allele ratio.
Biallelic expression was defined for maternal allele ratio comprised
between 40% and 60% and monoallelic expression for maternal
allele ratio comprised between 90% and 100% and 0% and 10%.
Examples of heterozygosity at the DNA level, biallelic (Gsa) and
monoallelic (NESP55) transcript expressions quantified by pyrose-
quencing are shown on Figure S4.
Allelic expression was analyzed for parental IMR90 and
GM04603 fibroblasts, all derived hiPSC (i90_c01, i90_c17,
4603_c27, and 4603_polyF), and for MSC (i90_c01, i90_c17, and
4603_c27) and neural (i90_c17 and 4603_c27) progenies (Table
1). Allelic expression was not studied in other samples either
because the rs7121 polymorphismwas present at the homozygous
state (all hESCs) or no RNA was available.Quantitative Real-Time PCR Analysis
Two qRT-PCR technologies were performed. The Sybr Green tech-
nology was used to detect Gsa, A/B, XLsa, NESP55, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) transcripts, and the
Taqman technology was used to detect GNAS-AS1. Real-time PCR
was carried out in a LightCycler LC480 system (Roche) to amplify
Gsa, A/B, XLsa, NESP55, and GAPDH transcripts and an Applied
Biosystems 7500 Fast Real-Time PCR System (Life Technologies)
to amplify GNAS-AS1.
One microliter of cDNA (see above) was amplified using the
LightCycler 480 SYBR Green I Master (Roche) for Gsa,
XLsa, NESP55, and GAPDH transcripts, the Luminaris HiGreen
qPCR Master Mix (Thermo Scientific) for A/B transcript, and
the GoTaq Probe qPCR Master Mix (Promega) for GNAS-AS1.
All PCR experiments were performed in triplicate. GNAS-AS1
mRNA level was quantified using a commercially Taqman assay
(Hs.PT.58.25851302; Integrated DNA Technologies). Specific pairs
of primerswere used to amplify other transcripts (Eurofins; primers
and PCR conditions available upon request).
Specificity of amplified qRT-PCR products was verified by per-
forming a melting curve analysis at the end of amplification
(Sybr Green technology only) and by migration on 1.5% agarose
gel electrophoresis. Gene expression was normalized with human
GAPDH as endogenous gene control using the formula NE =
Ereference
CTreference/Etarget
CTtarget (Simon 2003), where NE is the
normalized expression, E the efficiency of the PCR amplification
for the reference (Ereference) and the target (Etarget), and CT theuthors
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amplification were previously described (Mariot et al., 2011).
PCR amplification efficiency was comprised between 1.85 and
1.97.
Statistical Analysis
Methylation indices (MI) DMR at each DMR and dispersion of MI
were compared by Kruskal-Wallis test followed by Dunn’s multiple
comparison test. A p value < 0.05 was considered significant. To
calculate the dispersion of MI, the mean of DMRMI for each group
was calculated and the deviation of each sample to the mean calcu-
lated. Statistical analyseshavebeenperformedusingPrismsoftware.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and
can be found with this article online at http://dx.doi.org/10.1016/
j.stemcr.2014.07.002.
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